The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are ...

Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...

NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...

Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against the other hot stocks. What’s the US Stock Market Like in 2025? While the stock market in the ...

The stock’s fifty day moving average price is $26.81 and its two-hundred day moving average price is $23.61. Zai Lab Limited has a one year low of $13.48 and a one year high of $36.60. About Zai Lab ...

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered ...

Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved SHANGHAI ...

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...

We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against the other hot stocks.